Is fluoropyrimidindes without oxaliplatin optimal for the adjuvant treatment of mainstream stage III colon cancer?

Simple item page
dc.contributor.authorAbali, H.
dc.contributor.authorYavuz, S.
dc.contributor.authorCalikusu, Z.
dc.contributor.authorSeyrek, E.
dc.date.accessioned2023-02-21T12:32:31Z
dc.date.available2023-02-21T12:32:31Z
dc.date.issued2015-01-01
dc.description.abstractThis letter criticize the design of ACTS-CC trial
dc.description.abstractpatients received adjuvant oral fluoropyrimidine therapy without oxaliplatin. Authors believe that oxaplatin should have been a part of the treatment in both arms.
dc.description.issue1
dc.description.issueJAN
dc.description.pages245
dc.description.volume26
dc.identifier.doi10.1093/annonc/mdu473
dc.identifier.urihttps://hdl.handle.net/11443/1130
dc.identifier.urihttp://dx.doi.org/10.1093/annonc/mdu473
dc.identifier.wosWOS:000347416300037
dc.publisherOXFORD UNIV PRESS
dc.relation.ispartofANNALS OF ONCOLOGY
dc.titleIs fluoropyrimidindes without oxaliplatin optimal for the adjuvant treatment of mainstream stage III colon cancer?
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Is fluoropyrimidindes without oxaliplatin optimal for the adjuvant treatment of mainstream stage IIIcolon cancer.pdf
Size:
56.22 KB
Format:
Adobe Portable Document Format
Download

Collections

WOS